IDEaL Registry Overview
The IDEaL Registry is a cooperative, observational registry directed at Ig in the United States. The registry is a deliberate and purposeful assembly of clinical and humanistic knowledge that is intended to act as a longitudinal database tracking outcomes of routine clinical practice.
The registry's goal is to significantly contribute to the medical understanding of Ig therapy and to improve the quality of care for patients receiving Ig therapy in the United States through active publication of registry findings and disease management approaches.
The IDEaL program represents a unique and powerful method for the collection of:
- Patient Level / Humanistic Data / Quality of Life
- Physician Level / Practice Patterns
- Clinical Data / Therapeutic Outcomes
- Reimbursement / Impact on Treatment / Policy Decisions
Whereby:
- Accelerating innovation
- Producing faster knowledge gainImproving awareness of patient outcomes and disease burden
- Providing a clearer understanding of therapy impact on patients' quality of life
The objectives of the Registry are:
- To enhance the understanding of the variability, progression, and natural history of disease requiring Ig therapy with the ultimate goal of better guiding and assessing therapeutic intervention;
- To provide the Ig medical community with recommendations for monitoring patients and to provide reports on patient outcomes to help optimize patient care; and,
- To serve as an active knowledge base that can provide population-management information, which can be used to generate patient-management and practice-management tools; and,
- To add to the existing body of knowledge through peer-reviewed manuscripts, scientific abstracts and posters, medical symposia presentation, and patient education.
The study has been registered with ClinicalTrials.gov in accordance with the Food and Drug Administration Amendments Act of 2007.
View details of the IDEaL Patient Registry study on ClinicalTrials.gov.
